Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Donald Trump is executing a shock-and-awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...

Jim Cramer in a latest program on CNBC reminded viewers about the Trump playbook in the story market and said that he never ...

Shares in Novo Nordisk rose as much as 13 per cent on Friday ... Lilly’s diabetes drug Mounjaro and weight loss treatment Zepbound offer higher average weight loss than Wegovy.

Denmark’s Novo Nordisk (NOV: N) saw its shares rise as much as 13% to ... data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license agreement with Novo Nordisk (NOV ... Receive The Pharma Letter daily news bulletin ...

A new study found that pa­tients tak­ing GLP-1s to treat type 2 di­a­betes have a low­er risk of de­vel­op­ing Alzheimer’s dis­ease, po­ten­tial­ly open­ing the door … ...

Outgoing presidents traditionally leave a letter for the incoming president. Former President Joe Biden wished President Donald Trump "all the best for the next four years" in the letter he left ...

Few drugs have generated as much excitement as Novo Nordisk's (NYSE ... The agency will send its final offer on drug prices by Oct. 15, 2025. Drugmakers must accept or reject the final offer ...